Fig. 1.
DHHC3 ablation enhances chemotherapeutic drug effects. DHHC3 expression is shown for MDA-MB-231 and PC3 cells a stably ablated for DHHC3, or b transiently ablated for DHHC3 using control (C) or DHHC3 (D) shRNA or siRNA. c Cleaved caspase 3 expression (indicator of apoptosis) is shown for MDA-MB-231 cells transiently transfected with control (C), or DHHC3 siRNA (D3), and treated with DMSO, camptothecin, gefitinib and 5-Fu for 24 h at indicated concentrations in 5% complete media. HSP-70 expression is used as a loading control (bottom panel). d MDA-MB-231 cells (control, C; DHHC3 ablated, D3) were treated with DMSO, camptothecin, nifuroxazide, or lapatinib at the indicated concentrations, for 24 h. Actin expression is used as a loading control (bottom panel). e Cleaved caspase-3 expression is shown for MDA-MB-231 cells, either control ablated (C) or stably DHHC3-ablated (D3) and reconstituted with wild-type DHHC3 (D3R) or reconstituted with palmitoylation-deficient mutant DHHC3 (D3R+C/S). All cells were treated with DMSO alone, or camptothecin (in DMSO) for 24 h in 5% complete media. HSP-70 expression is used as a loading control (bottom panel)